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Targeting of prion-infected lymphoid cells to the
central nervous system accelerates prion
infection
Yael Friedman-Levi1, Romana Hoftberger2, Herbert Budka2, Tehila Mayer-Sonnenfeld1, Oded Abramsky1,
Haim Ovadia1 and Ruth Gabizon1*
Abstract
Background: Prions, composed of a misfolded protein designated PrPSc, are infectious agents causing fatal
neurodegenerative diseases. We have shown previously that, following induction of experimental autoimmune
encephalomyelitis, prion-infected mice succumb to disease significantly earlier than controls, concomitant with the
deposition of PrPSc aggregates in inflamed white matter areas. In the present work, we asked whether prion
disease acceleration by experimental autoimmune encephalomyelitis results from infiltration of viable prion-
infected immune cells into the central nervous system.
Methods: C57Bl/6 J mice underwent intraperitoneal inoculation with scrapie brain homogenates and were later
induced with experimental autoimmune encephalomyelitis by inoculation of MOG35-55 in complete Freund’s
adjuvant supplemented with pertussis toxin. Spleen and lymph node cells from the co-induced animals were
reactivated and subsequently injected into naïve mice as viable cells or as cell homogenates. Control groups were
infected with viable and homogenized scrapie immune cells only with complete Freund’s adjuvant. Prion disease
incubation times as well as levels and sites of PrPSc deposition were next evaluated.
Results: We first show that acceleration of prion disease by experimental autoimmune encephalomyelitis requires
the presence of high levels of spleen PrPSc. Next, we present evidence that mice infected with activated prion-
experimental autoimmune encephalomyelitis viable cells succumb to prion disease considerably faster than do
mice infected with equivalent cell extracts or other controls, concomitant with the deposition of PrPSc aggregates
in white matter areas in brains and spinal cords.
Conclusions: Our results indicate that inflammatory targeting of viable prion-infected immune cells to the central
nervous system accelerates prion disease propagation. We also show that in the absence of such targeting it is the load
of PrPSc in the inoculum that determines the infectivity titers for subsequent transmissions. Both of these conclusions
have important clinical implications as related to the risk of prion disease contamination of blood products.
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Background
Prion diseases are a group of fatal neurodegenerative
disorders that include Creutzfeldt-Jakob disease and
kuru in humans, bovine spongiform encephalopathy in
cattle, scrapie in sheep and goats, and chronic wasting
disease in deer [1]. This group of diseases is caused by
the accumulation of a misfolded and oxidized isoform of
PrPSc, a normal membrane protein believed to play a
role in the protection against oxidative insults [2,3]. All
forms of prion diseases are characterized by long incu-
bation periods, which in humans can sometimes amount
to decades [3-6]. Although the exact mechanism of
prion propagation is unknown, a general sequence of
events has been outlined that is consistent with most of
the available data [4]. First, and regardless of the route
of infection, prions replicate in lymphoid organs, as
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shown by the fact that both infectivity and accumulation
of PrPSc are initially detected in the spleens of the
infected animals [5-8]. Prions invade the nervous system
by a mechanism believed to involve transmigration of
infected lymphoid cells as well as retrograde transport
in ascending peripheral neural tracts [4,9-12]. Once
prions enter the brain, prion replication and PrPSc accu-
mulation seems to occur faster than in the lymphoid
system, leading to the certain death of the affected indi-
viduals [13-15]. In the presence of inflammatory condi-
tions affecting peripheral organs, activated
lymphoreticular cells induce deposition of PrPSc and
prion infectivity in the sites of infiltration in prion-
infected animals [16]. For example, mastitis in sheep
results in deposition of PrPSc in the inflamed mammary
glands [17].
While no differences in prion disease incubation time
or clinical symptoms were reported in these peripheral
infection cases, mice incubating scrapie and induced for
experimental autoimmune encephalomyelitis (EAE), an
autoimmune inflammatory disease of the central ner-
vous system (CNS) [18,19], died from a progressive neu-
rological disease long before the control mice
succumbed to classical scrapie [20]. Surprisingly, mice
affected by the scrapie-EAE syndrome showed almost
undetectable to high levels of brain PrPSc, demonstrating
that there is no correlation between the clinical status of
the affected scrapie-EAE mouse and PrPSc accumulation.
Immunostaining studies revealed PrPSc depositions in
the demyelinated white matter spinal cord areas of the
co-induced mice, mostly co-localized with hematopoietic
cell infiltrates. In classical scrapie, PrPSc aggregates are
mostly found in the gray matter [21].
In this project we investigated the mechanism of prion
disease acceleration by CNS inflammation. In particular,
we asked whether accelerated prion disease in the co-
induced animals requires the targeted delivery of PrPSc
to the CNS by activated immune cells. To this aim, we
compared the effect of EAE induction on prion disease
kinetics at several time points before and after infection
with scrapie and found that acceleration of disease is
the strongest at one month after prion infection, when
PrPSc is largely accumulated in immune organs such as
the spleen [22]. Next, we inoculated naïve mice with
viable or homogenized activated immune cells collected
from scrapie-EAE mice and controls. Only the activated
viable cells generated CNS inflammation and accelerated
prion disease, as compared with non-specific immune
activation, or with scrapie brain homogenates with simi-
lar PrPSc loads. Our results therefore suggest that EAE-
dependent acceleration of fatal prion disease results
from the infiltration of PrPSc loaded immune cells into
the CNS. Additional results presented here indicate that,
in the absence of such infiltration, incubation times of
prion disease relate mostly to the levels of the inocu-
lated PrPSc.
Methods
Animals
Female C57Bl/6 J mice were purchased from Harlan
(Hebrew University, Jerusalem, Israel) and housed in the
animal care facility in compliance with the standard
guidelines for animal care. All experiments were
approved by the Institutional Animal Care and Use
Committee.
Prion infection
Four- to five-week-old mice were inoculated by intra-
peritoneal injection with 100 μL or intracerebral injec-
tion with 50 μL of 1% scrapie brain homogenate. Mice
were followed closely for disease signs until disease
manifestation and killed when too sick to reach food
and water.
Experimental autoimmune encephalomyelitis induction
Five- to eight-week-old female C57BL/6 J mice were
immunized with an emulsion containing 300 μg of
MOG35-55 (70% purified; synthesized at the Hebrew
University, Jerusalem, Israel) solubilized in saline and an
equal volume of complete Freund’s adjuvant (CFA;
Sigma, Rehovot, Israel) supplemented with 5 mg/mL of
heat-killed mycobacteria Tuberculosis H37RA (Difco
Laboratories, Detroit, MI, USA). The inoculum (0.2 mL)
was injected subcutaneously in both flanks. On the day
of inoculation and 48 hours later, 100 ng of pertussis
toxin (List Biological Laboratories, Inc. Cambell, CA,
USA) in 0.1 mL saline was also administered by intra-
peritoneal injection. Control groups were inoculated the
same way but without MOG35-55.
Passive transfer of experimental autoimmune
encephalomyelitis
Nine days post induction mice were killed and cells
were obtained from the spleen and lymph nodes. Cells
were suspended in Roswell Park Memorial Institute
medium (Biological Industries, Beit Haemek, Israel) sup-
plemented with 10% fetal calf serum, 1 mM L-gluta-
mine, antibiotics, MOG35-55 (20 μg/mL) and mouse
recombinant IL-2 (50 units/mL; Peprotech, Rocky Hill,
NJ, USA) and incubated for three days in a CO2 humi-
dified incubator. Cells were harvested and live cells were
separated with Ficoll-Paque (GE Healthcare Bio-Sciences
AB, Uppsala, Sweden) and injected into naïve mice. In
control groups of cells extracts, cells were frozen after
separation, thawed three times and then injected into
naïve mice. On the day of inoculation and 48 hours
later, 100 ng of pertussis toxin in 0.1 mL saline was also
administered by intraperitoneal injection. Mice were
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followed for clinical symptoms of EAE and evaluated
according to a 0 to 6 point score (0 represents no clini-
cal signs and 6 represents death as a result of disease).
Western blot: PrP immunoblots of brains and spleens
Brains and spleens from mice in all experimental groups
were homogenized in 10 volumes of 10 mM Tris-HCl
(pH 7.5) containing 300 mM sucrose. Homogenates
were normalized for protein level, digested with 40 μg/
mL proteinase K (Sigma), and immunoblotted with anti-
PrP monoclonal antibody IPC1 (Sigma) or monoclonal
antibody 6H4 (Prionics, Schlieren, Switzerland), 40 μL
in each lane for brains and 100 μL in each lane for
spleen homogenates.
Pathological examinations
Histological evaluations were performed on paraffin-
embedded sections of brain and spinal cord samples.
Sections were stained with luxol fast blue/Periodic acid
Schiff (PAS) to assess demyelination. Consecutive sec-
tions were used for immunohistochemistry with antibo-
dies against the following targets: macrophages and
activated microglia (anti-MAC3; BD Pharmingen, San
Diego, CA, USA); T-cells (anti-CD3; Serotec, Oxford,
UK); and prion protein (anti-PrP 6H4; Prionics).
Statistical analysis
The clinical scores of disease in groups of animals with
EAE and EAE + scrapie were compared using Kruskal-
Wallis one-way analysis of variance on ranks. The survi-
val curves were compared using chi-squared test.
Results and discussion
Acceleration of prion disease by experimental
autoimmune encephalomyelitis may depend on spleen
PrPSc levels
Regardless of the route of prion infection, PrPSc is first
accumulated in immune organs such as the spleen and
lymph nodes and appears in the infected brains much
later in the incubation period [22,23]. In the scrapie
RML model (mouse), it takes one month after intracer-
ebral or intraperitoneal infection for PrPSc to accumu-
late in the spleen at high levels. Indeed, Figure 1A
shows that while no PrPSc was detected in the brain one
month after intraperitoneal infection with a scrapie
brain homogenate, PrPSc was easily detectable in the
spleen at this time point. To test whether the presence
of PrPSc in immune organs is required for disease accel-
eration by CNS inflammation, we induced MOG-EAE
both one week and one month after scrapie infection
(intracerebral injection) of C57Bl/6 J female mice. Ani-
mals were followed for clinical symptoms of both EAE
and scrapie (Figure 1C). Figure 1B shows no difference
in the severity of EAE signs, such as paralysis of the
lower limbs, during the first 30 days in the groups
induced for EAE after prion infection as compared to
control EAE groups [24]. While most mice recovered
from the acute disease at this point, the group induced
for EAE one month after scrapie infection continued to
deteriorate, demonstrating new neurological signs such
as tail rigidity, kyphosis, ataxia, tremor and bradykinesia,
which are classical characteristics of prion disease [25].
Similar signs were observed at 80 days or later in the
group induced for EAE one week after scrapie infection.
Figure 1D depicts the survival of mice from these
groups as compared to control scrapie-infected mice.
Indeed, while mice induced for EAE one week after
prion infection showed some acceleration of disease
progression (median: 155 days) as compared to scrapie
controls (median: 175 days), a much larger difference in
survival was observed between the scrapie control (med-
ian: 175 days) and the group also induced for EAE at
one month of prion infection (median: 60 days). Only a
marginal acceleration of disease was observed when
EAE was induced in the mice before scrapie infection
(not shown). These results indicate that the rate of
prion disease acceleration by CNS inflammation may
depend on the levels of PrPSc accumulating in lymphoid
organs at the different time points.
Accelerated disease in mice infected with scrapie-
experimental autoimmune encephalomyelitis-activated
immune cells
We next tested the incubation time resulting from prion
infection of naïve mice either with viable or with homo-
genized scrapie-EAE immune cells. To this effect,
C57Bl/6 J mice were infected intraperitoneally with scra-
pie RML prions and one month later induced either for
EAE (MOG (myelin oligodendrocyte glycoprotein) +
CFA + pertussis toxin) or for adjuvant only inflamma-
tion (CFA + pertussis toxin). Nine days thereafter, scra-
pie-EAE mice and controls were killed, their spleens and
lymph nodes harvested and reactivated in vitro with
MOG and subsequently enriched for viable cells only
(see Methods). An outline for these experiments is
depicted in Figure 2. Before inoculation into naïve mice
groups, cell fractions were tested for PrPSc levels as
compared to sequential dilutions of prion-infected brain
and spleen samples (Figure 3A). Next, groups of naïve
mice (four to five animals in each of two combined
experiments) were inoculated intraperitoneally with the
viable cells or with their homogenates, as well as with
two dilutions (10-2 and 10-4) of scrapie-infected brain
homogenates. Each mouse was infected with the equiva-
lent of cells per homogenate harvested from two donor
mice, comprising a PrPSc load comparable to that of a
10-4 dilution of scrapie-infected brains. All groups of
infected mice were followed closely for signs of
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neurological disease. Mild EAE signs, such as limp tail
and hind limb weakness (paraparesis), were observed
only in the mice inoculated with scrapie-EAE viable
cells (Figure 3B), starting at day 30 post infection. Figure
3C presents the survival data for the mice in the
different experimental groups. Mice from the groups
infected with CFA only-induced cells, as well as with
cell homogenates and 10-4 brain dilutions, developed
fatal prion disease at about 220 days, indicating no dif-
ference in the PrPSc to infectivity ratio of the
Figure 1 PrPSc in spleen is required for the acceleration of prion disease by experimental autoimmune encephalomyelitis. (A) Brain and
spleen samples from scrapie-infected mice (C57Bl/6 J, RML strain) at several incubation points (1 week, 1 month, sick) were tested for the levels
of proteinase K digested PrPSc. (B) Prion-infected mice were induced for MOG-EAE one week (n = 5) and one month (n = 6) after prion infection
and followed for signs of disease. The clinical scores of the group induced with EAE one month post infection were significantly different (P =
0.025) as compared to naïve mice induced for EAE (n = 6). The clinical scores of mice with EAE induced one week post infection were not
statistically different (P = 0.5) as compared to naïve mice induced for EAE (n = 6). (C) Table presenting chronological symptoms of the scrapie-
EAE syndrome. (D) Survival curves of mice from the designated groups. Scrapie/EAE at one month was statistically different (P = 0.0033) as
compared to the corresponding scrapie/EAE at one week.
Figure 2 Outline of scrapie-experimental autoimmune encephalomyelitis transfer experiments. C57Bl/6 J mice were induced for either
MOG-EAE or CFA disease one month after intraperitoneal infection with scrapie RML. Nine days later mice were killed and immune cells
collected and incubated with MOG for three days, before their inoculation as viable or homogenate samples into naïve mice. Control scrapie-
infected brain samples were also inoculated in naïve mice.
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homogenates from cells and brain, as well as for viable
cells induced only with CFA. Contrarily, the group
infected with viable scrapie-EAE cells succumbed to
prion disease 30 days earlier, even before the mice
infected with a 10-2 scrapie brain dilution. These results
indicate that the PrPSc to infectivity ratio is at least 100
times lower in the activated viable cells, consistent with
the possibility that accelerated prion disease is caused
by the inflammation-dependent targeting of prions into
the CNS.
PrPSc in white matter demyelinated areas
The pathological examination of scrapie-infected mice
induced for EAE [20] revealed depositions of PrPSc in
white matter inflamed areas. Figure 4 shows the differ-
ences in demyelination and PrPSc deposition in the
white matter spinal cords of naïve mice infected with
viable as compared to homogenized scrapie-EAE cells.
Indeed, spinal cords of mice infected with viable scra-
pie-EAE cells present marked subpial demyelination co-
localized with activated microglia, macrophages and
moderate levels of PrPSc accumulation, mainly at the
border of the lesion (Figure 4). Due to the long time
lapse from infection with the viable cells to prion dis-
ease manifestation, it is hard to determine whether
prion-infected macrophages were the ones that depos-
ited the PrPSc in the demyelinated spinal cord, or
whether their presence represents the engulfing of other
prion-infected cells, such as T-cells. Such a co-localiza-
tion between PrPSc, Mac-3 and demyelination was not
present in the spinal cords of mice infected with cells
homogenates. Extensive PrPSc deposition was also
observed in brain white matter areas such as the com-
missura anterior of mice infected with scrapie-EAE
viable cells (Figure 5), again contrary to the low levels of
PrPSc observed in the brain white matter of mice
infected with cell homogenates. These results are again
consistent with the idea that viable prion-infected
Figure 3 Infection of mice with viable scrapie-experimental
autoimmune encephalomyelitis immune cells shortened the
prion disease incubation period. (A) PrPSc levels in brains and
immune samples. (B) EAE clinical scores in mice inoculated with
viable or homogenated cells after activation ex vivo for three days
with MOG. (C) Survival curves of mice infected with the designated
inocula. The survival curve of group 1 was significantly different (P <
0.05) as compared to survival curves of groups 2,3,4 and 6. Results
represent eight to ten mice in each category.
Figure 4 Pathology spinal cords . Upper panel: viable cells.
Pathology is characterized by marked subpial demyelination (A, B,
Luxol fast blue). The rectangle in (A) marks the region enlarged in
(B-D). The demyelinated areas show some activated microglia and
macrophages (C, Mac-3) as well as moderate PrPSc deposition,
which is most abundant at the lesion border (D, arrowheads, PrPSc).
Lower panel: homogenated cells. In contrast, control animals were
devoid of demyelination (E, F, luxol fast blue). The rectangle in (E)
marks the region enlarged in (F-H). White matter only reveals some
activated microglia (G, Mac-3) but no PrPSc deposition (H).
Figure 5 Pathology of brains. Upper panel: viable cells. The
commissura anterior area of mice infected with viable cells (A, B,
Luxol Fast Blue) showed extensive PrPSc deposition (C, PrPSc) in
contrast to animals infected with cell homogenates (D, E, Luxol Fast
Blue) that revealed less PrPSc deposition in this anatomical region (F,
PrPSc).
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immune cells activated against myelin components, such
as MOG in this case, may carry PrPSc into white matter
CNS areas, a feature not frequently seen in prion infec-
tion [21]. For unknown reasons, this route of infection
is more virulent, as compared to classic prion neuroin-
vasion, and is believed to involve retrograde transport of
prions to the brain. Both routes of neuroinvasion may
occur in parallel and produce additive signs of disease.
Transmission of disease from scrapie-experimental
autoimmune encephalomyelitis inoculated brains
We have shown in Figure 3 that while most of the
inoculated samples comprised similar levels of PrPSc, the
sample consisting of viable scrapie-EAE cells generated
disease in the naïve mice significantly earlier than all
others, indicating that levels of PrPSc are not the only
designator of prion disease incubation time. In our pre-
vious work [20], we showed that mice may succumb to
the co-induced scrapie-EAE disease at similar incubation
times with very different levels of brain PrPSc, those
varying from undetectable levels to the high levels
observed in mice with classical scrapie. To this effect,
we next investigated whether mice succumbing to the
co-induced disease generate a new prion strain that can
transmit disease independent of PrPSc inoculum levels,
or whether disease transmission from these mice corre-
late with the accumulated PrPSc levels when in brain
homogenates.
To separate these possibilities, we infected groups of 5
C57Bl/6 J mice with the brain homogenates of the sam-
ples described in Figure 6. Group 1 was inoculated with
the brain homogenate from a normal mouse induced for
EAE, group 2 was infected with the homogenate of a
still healthy mouse incubating classical scrapie, and
group 3 was infected with the homogenate of a scrapie
sick mouse. Groups 4 to 6 were infected with brains of
mice that succumbed to the scrapie-EAE co-induced
disease at a similar time point; however, each with a dif-
ferent level of brain PrPSc. Figure 6 shows that samples
1, 2 and 4 could not transmit disease to naïve mice for
at least 300 days post infection. This is specifically sur-
prising for sample 4, generated from the brain of a
mouse that succumbed to the co-induced disease. Sam-
ple 5, which presents marginal levels of PrPSc, generated
intermediate levels of infectivity in the recipient group.
Only mice inoculated with samples 3 and 6 (high levels
of PrPSc) succumbed to prion disease, at short incuba-
tion times. These results indicate that the scrapie-EAE
syndrome, while causing accelerated disease, does not
induce the replication and accumulation of prions that
can further transmit disease in the absence of PrPSc.
These results are therefore consistent with the notion
that inflammation-dependent targeting of PrPSc can
accelerate disease regardless of the inoculated PrPSc
levels. In the absence of such PrPSc targeting, as is the
case for the total brain homogenates in these second
transmission experiments, it is the levels of PrPSc that
determine the incubation time of disease manifestation.
Conclusions
We have shown in this work that acceleration of prion
disease by CNS inflammation, as is the case for EAE
induction, requires the presence of substantial levels of
PrPSc in the immune cells of prion-infected mice. Such
PrPSc-rich cells may then be targeted by CNS inflamma-
tion for infiltration into the CNS, as demonstrated by
the presence of PrPSc deposits in white mater areas of
brains and spinal cords. This was true for mice induced
with EAE a month after scrapie infection [20] as well as
for mice infected directly with viable and activated scra-
pie-EAE cells (Figures 3 and 4). Our experiments also
show that the inflammation-mediated disease does not
constitute a more virulent prion strain, since secondary
transmission from scrapie-EAE mouse homogenized
brain samples indicated that prion titers were dependent
mostly on the inoculated levels of PrPSc. These results
are consistent with previous observations that suggest
inflammation may affect the sites of PrPSc accumulation
[16,17] and, in the case of CNS inflammation, accelerate
the presentation of fatal disease [20], sometimes in the
absence of high levels of PrPSc in the brains of the
affected animals. It is possible that low levels of prions
Figure 6 Secondary transmission of co-induced brain
homogenates depends on PrPSc levels. (A) Sample legend. (B)
Immunoblots presenting levels of PrPSc in the samples described in
A. (C) Survival curves of mice (n = 5 for each group) infected with
the samples described in A and B. The survival curve of scrapie-EAE
(PrPSc high) was significantly different (P < 0.02) as compared to
scrapie-EAE (PrPSc low).
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that have infiltrated into white matter areas are more
toxic and facilitate the propagation of disease in a more
efficient way. Both mechanisms, retrograde transport of
prions and inflammation-dependent neuroinvasion, may
occur distinctively or in parallel, explaining how simi-
larly sick mice present different levels of brain PrPSc at
the end point of disease. It is also possible that a vari-
able balance between EAE-linked and scrapie symptoms
can account for this phenomenon.
The fact that incubation times for second-generation
transmission of disease from homogenates of scrapie-
EAE brains were independent of the clinical status of
donor mice and related only to PrPSc levels indicates
that inflammation did not change the virulence proper-
ties of the initial prion strain, but rather accelerated the
targeting of the infectious agent to vital areas, resulting
in a shorter disease. This may explain why endogenous
blood prions carry more infectivity than predicted from
their low blood PrPSc content [4,26,27]. Indeed, our
results suggest that infection by viable cells carrying
PrPSc may be more rapid and that the infectivity of a
specific blood sample may depend not only on the prion
incubation status of the blood donor, but also on the
inflammatory state of both the donor and recipient on
the day of the transfusion.
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